MXPA03008072A - Forma de dosificacion farmaceutica de peptido oral y metodo de produccion. - Google Patents

Forma de dosificacion farmaceutica de peptido oral y metodo de produccion.

Info

Publication number
MXPA03008072A
MXPA03008072A MXPA03008072A MXPA03008072A MXPA03008072A MX PA03008072 A MXPA03008072 A MX PA03008072A MX PA03008072 A MXPA03008072 A MX PA03008072A MX PA03008072 A MXPA03008072 A MX PA03008072A MX PA03008072 A MXPA03008072 A MX PA03008072A
Authority
MX
Mexico
Prior art keywords
peptide
lamination
dosage form
lowering agent
layer
Prior art date
Application number
MXPA03008072A
Other languages
English (en)
Spanish (es)
Inventor
Ashlesh Sheth
Original Assignee
Unigene Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unigene Lab Inc filed Critical Unigene Lab Inc
Publication of MXPA03008072A publication Critical patent/MXPA03008072A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03008072A 2001-03-08 2002-03-08 Forma de dosificacion farmaceutica de peptido oral y metodo de produccion. MXPA03008072A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27431701P 2001-03-08 2001-03-08
PCT/US2002/007197 WO2002072075A1 (en) 2001-03-08 2002-03-08 Oral peptide pharmaceutical dosage form and method of production

Publications (1)

Publication Number Publication Date
MXPA03008072A true MXPA03008072A (es) 2004-03-16

Family

ID=23047692

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008072A MXPA03008072A (es) 2001-03-08 2002-03-08 Forma de dosificacion farmaceutica de peptido oral y metodo de produccion.

Country Status (8)

Country Link
US (1) US7316819B2 (https=)
EP (1) EP1365747A4 (https=)
JP (2) JP2004525123A (https=)
AU (1) AU2002306681B2 (https=)
CA (1) CA2440578C (https=)
MX (1) MXPA03008072A (https=)
NZ (1) NZ527844A (https=)
WO (1) WO2002072075A1 (https=)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091708A1 (en) * 1997-03-13 2003-05-15 Garwood Anthony J.M. Irradiation in low oxygen environment
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US7156652B2 (en) * 2003-10-03 2007-01-02 Daiwa Kasei Industry Co., Ltd. Motor-driven injection molding apparatus
US8709476B2 (en) * 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
PE20142101A1 (es) * 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
EP1785431B1 (en) * 2004-08-30 2016-01-20 Toray Industries, Inc. Fractionation apparatus
JP4846799B2 (ja) * 2005-07-05 2011-12-28 バイオテンプト ベー．フェー． 腫瘍の治療
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
AU2006236006B2 (en) * 2006-04-13 2012-09-06 The University Of Queensland Cyclised a-conotoxin peptides
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
DK2120991T3 (da) * 2007-02-12 2014-04-28 Biotempt Bv Behandling af traumatisk blødning med korte oligopeptider
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20100303901A1 (en) * 2007-04-26 2010-12-02 Eyal Shimoni Oral delivery of proteins and peptides
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008148180A1 (en) * 2007-06-04 2008-12-11 Bce Inc. Methods and systems for validating online transactions using location information
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
EP2255794A1 (en) * 2009-05-29 2010-12-01 H e x a l Aktiengesellschaft Enteric coating
AU2010339907A1 (en) 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CN103003296A (zh) 2010-07-09 2013-03-27 阿菲博迪公司 多肽
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2683902T3 (es) 2011-06-14 2018-09-28 Hale Biopharma Ventures, Llc Administración de benzodiacepina
EP3357540A1 (en) 2011-11-02 2018-08-08 KeyBioscience AG Combination of calcitonin mimetic and insulin sensitizer
US9006172B2 (en) 2011-11-02 2015-04-14 Keybioscience Ag Peptide analogs for treating diseases and disorders
WO2013128450A1 (en) 2012-03-01 2013-09-06 Yeda Research And Development Co. Ltd. Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes
JP2015512902A (ja) * 2012-03-28 2015-04-30 アフィボディ・アーベー 経口投与
WO2014048977A1 (en) 2012-09-25 2014-04-03 Affibody Ab Albumin binding polzpeptide
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9457086B2 (en) 2013-03-05 2016-10-04 Enteris Biopharma, Inc. Pharmaceuticals for oral delivery
US10031183B2 (en) * 2013-03-07 2018-07-24 Rai Strategic Holdings, Inc. Spent cartridge detection method and system for an electronic smoking article
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6661531B2 (ja) 2013-10-10 2020-03-11 シナジー ファーマシューティカルズ インコーポレイテッド オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト
CN105722854B (zh) 2013-11-14 2020-08-04 关键生物科学有限公司 用于治疗疾病和病症的降钙素模拟物
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
CN103645665B (zh) * 2013-12-24 2016-06-08 南京富士通南大软件技术有限公司 一种可编程信号发生器及其信号发生方法
EP3122768A2 (en) 2014-03-27 2017-02-01 Yeda Research and Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
DK3244878T3 (da) * 2015-01-12 2022-10-17 Enteris Biopharma Inc Faste orale sammensætningsformer
US10653744B2 (en) 2016-01-11 2020-05-19 Bausch Health Ireland Limited Formulations and methods for treating ulcerative colitis
CN118634202A (zh) * 2016-08-05 2024-09-13 帕克治疗公司 室温稳定的口服降钙素制剂
US20180055090A1 (en) * 2016-08-31 2018-03-01 Altria Client Services Llc Methods and systems for cartridge identification
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
CA3150380A1 (en) 2019-08-16 2021-02-25 9 Meters Biopharma, Inc. Larazotide formulations
JP2024521399A (ja) 2021-06-10 2024-05-31 ニューレリス、インク． 小児患者における発作性障害を治療するための組成物および方法
EP4226918A1 (en) 2022-02-15 2023-08-16 Filip Majewski Pharmaceutical single dosage form for oral delivery of peptides
DK202430306A1 (en) * 2024-06-10 2025-12-19 Merdury Biopharmaceutical Corp Oral peptide drug structure and manufacturing method thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944311A (ja) * 1982-09-07 1984-03-12 Santen Pharmaceut Co Ltd 徐放性顆粒およびその製造法
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
RU2113220C1 (ru) * 1991-07-24 1998-06-20 Энзакор Пропертиз Лимитед Композиция, способ лечения кишечной инфекции, способ неспецифической стимуляции имvунной системы, способ доставки биологически активного материала в верхние отделы тонкого кишечника
US5614219A (en) * 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
JP3172749B2 (ja) * 1992-02-17 2001-06-04 ライオン株式会社 イブプロフェン含有製剤
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
ES2188657T3 (es) * 1994-04-22 2003-07-01 Yamanouchi Pharma Co Ltd Sistema para la liberacion especifica en el colon de un farmaco.
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
JPH08325145A (ja) * 1995-05-26 1996-12-10 Sumitomo Pharmaceut Co Ltd 安定なイソプロピルアンチピリン含有製剤
SG80553A1 (en) * 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US6039975A (en) * 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
WO1997021448A1 (en) * 1995-12-13 1997-06-19 Dullatur Limited A calcitonin preparation
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
JP4549529B2 (ja) * 1998-01-30 2010-09-22 サイオス，インコーポレーテッド ペプチドまたはタンパク質の制御放出送達
WO1999064449A2 (en) 1998-06-10 1999-12-16 The Queen's University Of Belfast Cell-permeable peptide
GB9824604D0 (en) * 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
JP3796562B2 (ja) * 1999-05-26 2006-07-12 ライオン株式会社 多層錠、多層錠の製造方法及び多層錠の剥離抑制方法
JP2001055322A (ja) * 1999-08-18 2001-02-27 Tanabe Seiyaku Co Ltd パルス放出型製剤
WO2001027154A2 (en) 1999-09-27 2001-04-19 Mahony Daniel J O Membrane translocating peptide drug delivery system

Also Published As

Publication number Publication date
JP2010184945A (ja) 2010-08-26
EP1365747A1 (en) 2003-12-03
JP2004525123A (ja) 2004-08-19
CA2440578C (en) 2009-05-26
US20030017203A1 (en) 2003-01-23
WO2002072075A1 (en) 2002-09-19
US7316819B2 (en) 2008-01-08
AU2002306681B2 (en) 2006-02-02
CA2440578A1 (en) 2002-09-19
NZ527844A (en) 2005-08-26
EP1365747A4 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
MXPA03008072A (es) Forma de dosificacion farmaceutica de peptido oral y metodo de produccion.
WO2007070450A3 (en) Fast-acting oral peptide pharmaceutical products
CA2294744A1 (en) Multiple unit effervescent dosage form
WO2006102446A3 (en) Multi-particulate, modified-released colonic composition
MY126555A (en) Oral pharmaceutical extended release dosage form
JP2004525123A5 (https=)
MX9604497A (es) Nueva formulacion farmaceutica y procedimiento.
UA41946C2 (uk) Оральна фармацевтична складова одинична дозована форма у вигляді таблетки, спосіб її одержання, упаковка у вигляді блістера та спосіб інгібування секреції шлункової кислоти і/або лікування шлунково-кишкових запальних захворювань
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
MX9706769A (es) Formas de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y un agente procinetico.
SG149667A1 (en) Extended release oral dosage composition
WO2004064815A8 (en) Oral dosage formulation
WO2012174117A3 (en) Aromatic-cationic peptides and uses of same
MX9706767A (es) Formas orales de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y una droga antiinflamatoria no esteroide (daine).
CA2396159A1 (en) Novel substituted benzimidazole dosage forms and method of using same
AR002275A1 (es) Forma de dosificacion farmaceutica oral, procedimiento para la manufactura de una forma de dosificacion fija, y uso de dicha forma de dosificacionfarmaceutica oral.
HK1038701A1 (zh) 口脈冲劑量藥物釋放系統
WO2003039519A3 (es) Forma de dosificación de liberación controlada dual
CA2382387A1 (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
CA2374877A1 (en) Pharmaceutical formulations and methods comprising intranasal morphine
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2004064758A3 (en) Improved oral delivery of peptides
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
WO2002098453A3 (en) Orally administering parathyroid hormone and calcitonin
WO2000069390A3 (en) Compositions for improving bioavailability of orally administered drugs

Legal Events

Date Code Title Description
FG Grant or registration